Regulation of cell survival by sphingosine-1-phosphate receptor S1P 1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1

Cell Death and Disease

Volumn 4, Issue 11, 2013, Pages

  Rutherford, C ^a   Childs, S ^a   Ohotski, J ^a,b   McGlynn, L ^a   Riddick, M ^a   MacFarlane, S ^a   Tasker, D ^a   Pyne, S ^b   Pyne, N J ^b   Edwards, J ^a   Palmer, T M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Apoptosis; Bim; Breast cancer; Mcl 1; S1P1; Sphingosine 1 phosphate

Indexed keywords

BIM PROTEIN; FINGOLIMOD; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN MCL 1; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FIBROBLAST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REGULATORY MECHANISM; TISSUE MICROARRAY; TUMOR CELL; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULARIZATION;

APOPTOSIS REGULATORY PROTEINS; CELL SURVIVAL; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS; RECEPTORS, LYSOSPHINGOLIPID;

EID: 84889602370     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.455     Document Type: Article

References (56)

1. Kihara A, Igarashi Y. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim Biophys Acta 2008; 1781: 496-502
2. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009; 82: 201-211
3. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 2011; 36: 97-107
4. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011; 11: 403-415
5. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009; 78: 743-768
6. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9: 883-897
7. Singleton PA, Dudek SM, Chiang ET, Garcia JG. Regulation of sphingosine 1-phosphateinduced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-Actinin. FASEB J 2005; 19: 1646-1656
8. Jung B, Obinata H, Galvani S, Mendelson K, Ding BS, Skoura A, et al. Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev Cell 2012; 23: 600-610
9. Gaengel K, Niaudet C, Hagikura K, Laviña B, Muhl L, Hofmann JJ, et al. The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev Cell 2012; 23: 587-599
10. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006; 66: 221-231
11. Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010; 16: 1421-1428
12. Pyne NJ, Pyne S. Sphingosine 1-phosphate is the missing link between inflammation and colon cancer. Cancer Cell 2013; 23: 5-7
13. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-Associated cancer. Cancer Cell 2013; 23: 107-120
14. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310
15. Giam M, Huang DC, Bouillet P. BH3-only proteins and their roles in programmed cell death. Oncogene 2008; 27: S128-S136
16. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003; 162: 613-622
17. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, et al. ERK1/ 2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 2007; 26: 2856-2867
18. Dehan E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN, et al. BetaTrCP-And Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 2009; 33: 109-116
19. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349
20. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-21457
21. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, et al. Activation of ERK1/2 by deltaRaf-1:ER. represses Bim expression independently of the JNK or PI3K pathways. Oncogene 2003; 22: 1281-1293
22. Molton SA, Todd DE, Cook SJ. Selective activation of the c-Jun N-Terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3'-kinase (PI3K) pathway is inhibited. Oncogene 2003; 22: 4690-4701
23. Pyne S, Bittman R, Pyne NJ. Sphingosine kinase inhibitors and cancer: Seeking the golden sword of Hercules. Cancer Res 2011; 71: 6576-6582
24. Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R, et al. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a 'come-Andget-me' signal. FASEB J 2008; 22: 2629-2638
25. Waters CM, Long J, Gorshkova I, Fujiwara Y, Connell M, Belmonte KE, et al. Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1. FASEB J 2006; 20: 509-511
26. Long JS, Natarajan V, Tigyi G, Pyne S, Pyne NJ. The functional PDGFbeta receptor-S1P1 receptor signaling complex is involved in regulating migration of mouse embryonic fibroblasts in response to platelet derived growth factor. Prostaglandins Other Lipid Mediat 2006; 80: 74-80
27. Pyne NJ, Pyne S. Receptor tyrosine kinase-G-protein coupled receptor signalling platforms: Out of the shadow? Trends Pharmacol Sci 2011; 32: 443-450
28. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278: 18811-18816
29. Waters C, Sambi B, Kong KC, Thompson D, Pitson SM, Pyne S, et al. Sphingosine 1-phosphate and platelet-derived growth factor (PDGF) act via PDGF beta receptorsphingosine 1-phosphate receptor complexes in airway smooth muscle cells. J Biol Chem 2003; 278: 6282-6290
30. DeFea KA, Zalevsky J, Thoma MS, Dé ry O, Mullins RD, Bunnett NW. b-Arrestindependent endocytosis of proteinase-Activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 2000; 148: 1267-1281
31. Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, Oakley RH, et al. The stability of the G protein-coupled receptor-beta-Arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem 2003; 278: 6258-6267
32. Thompson B, Ancellin N, Fernandez SM, Hla T, Sháafi RI. Protein kinase C-Alpha and sphingosine 1-phosphate-dependent signaling in endothelial cell. Prostaglandins Other Lipid Mediat 2006; 80: 15-27
33. Igarashi J, Erwin PA, Dantas AP, Chen H, Michel T. VEGF induces S1P1 receptors in endothelial cells: Implications for cross-Talk between sphingolipid and growth factor receptors. Proc Natl Acad Sci USA 2003; 100: 10664-10669
34. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011; 1813: 1978-1986
35. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281-294
36. Austin M, Cook SJ. Increased expression of Mcl-1 is required for protection against serum starvation in phosphatase and tensin homologue on chromosome 10 null mouse embryonic fibroblasts, but repression of Bim is favored in human glioblastomas. J Biol Chem 2005; 280: 33280-33288
37. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104-109
38. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006; 21: 749-760
39. Thomas A, Pepper C, Hoy T, Bentley P. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 2004; 45: 997-1008
40. Kwon YG, Min JK, Kim KM, Lee DJ, Billiar TR, Kim YM. Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production. J Biol Chem 2001; 276: 10627-10633
41. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674
42. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008; 68: 6109-6117
43. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, et al. Involvement of Akt and mTOR in chemotherapeutic-And hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011; 10: 3003-3015
44. McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, et al. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 2009; 15: 1487-1495
45. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM, et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 2010; 177: 2205-2215
46. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100: 194-199
47. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. J Hepatol 2006; 44: 151-157
48. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67: 782-791
49. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, et al. Seed analysis of off-Target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007; 26: 3972-3979
50. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858
51. Sun HL, Tsai AC, Pan SL, Ding Q, Yamaguchi H, Lin CN, et al. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation. Clin Cancer Res 2009; 15: 4904-4914
52. Kennedy PC, Zhu R, Huang T, Tomsig JL, Mathews TP, David M, et al. Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther 2011; 338: 879-889
53. Watterson KR, Johnston E, Chalmers C, Pronin A, Cook SJ, Benovic JL, et al. Dual regulation of EDG1/S1P(1) receptor phosphorylation and internalization by protein kinase C and G-protein-coupled receptor kinase 2. J Biol Chem 2002; 277: 5767-5777
54. Sands WA, Woolson HD, Milne GR, Rutherford C, Palmer TM. Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells. Mol Cell Biol 2006; 26: 6333-6346
55. Woolson HD, Thomson VS, Rutherford C, Yarwood SJ, Palmer TM. Selective inhibition of cytokine-Activated extracellular signal-regulated kinase by cyclic AMP via Epac1-dependent induction of suppressor of cytokine signalling-3. Cell Signal 2009; 21: 1706-1715
56. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004; 6: R246-R251